Effectiveness of the Sana Device on Fibromyalgia Symptoms

Quality of Life Clinical Trial

Official title:

A Confirmatory Investigation of the Effectiveness of Sana Treatment in Fibromyalgia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05394610
• Other study ID #: 850524
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: June 2025

Study information

• Verified date: November 2023
• Source: Sana Health
• Contact: Melanie Maron
• Phone: 2157461419
• Email: fibromyalgiastudy[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR). It is a two arm study in which subjects will be randomly assigned to either active device group or sham-controlled group.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 166
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Willing to and capable of providing written informed consent prior to the conduct of any study-related procedures.

• Male or female, 18 to 65 years of age, inclusive.

• Have a history of experiencing fibromyalgia - like symptoms for a minimum of 36 months (3 years) prior to Screening.

• Subject must be in good physical health based on physical exams, vitals, and/or self-reporting. For subjects where there may not be sufficient recent medical records to document general good health the participant will be asked to self-report at the investigator's discretion.

• Any analgesic medications and medication dosages must be at approximately stable levels for at least 8 weeks prior to enrollment and remain steady throughout the study.

• A total score on the Generalized Anxiety Disorder 7-item scale (GAD-7) of 5 or above.

• A total score on the Patient Health Questionnaire 8-item (PHQ-8) of 5 or above.

• A total score on the STOP-Bang questionnaire of 3 or below.

• Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the Treatment Phase.

• Able to understand, speak and read English sufficient for the completion of study assessments.

Exclusion Criteria:

• Pregnant or lactating females as self-reported.

• History or presence of photo-sensitive epilepsy or other photo-sensitive conditions.

• History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo.

• History of presence of condition (s) that meet the criteria for major depressive disorder (MDD), bipolar disorder, or any other personality disorders, at the discretion of the investigator.

• Presence of cancer pain, acute pain following injury or other severe pain not primarily associated with fibromyalgia, at discretion of the investigator.

• Surgery or trauma requiring rehabilitation within the last 12 weeks.

• Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes.

• Deafness in one or both ears, perceived differences in hearing between ears, or tinnitus.

• Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion).

• Presence of inflammation or broken skin around the eyes in the area of the mask.

• Presence of narcolepsy or untreated sleep apnea or requiring treatment for sleep apnea such that use of device at bedtime will be interrupted, at discretion of the investigator.

• At the discretion of the Investigator, participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days.

• Any pending legal action that could prohibit participation or compliance in the study.

• Recent history of or current evidence of suicidal ideation or active suicidal behavior, based on medical history, at the discretion of the investigator.

• Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the subject from safely participating in study.

• Employment by the investigator or the study site, with direct involvement in the proposed study or other studies under the direction of the investigator or study site, or a family member of an employee or of the investigator.

Related Conditions & MeSH terms

• Chronic Pain
• Fibromyalgia
• Myofascial Pain Syndromes
• Pain, Chronic
• Quality of Life

Intervention

Device:
• Sana Device
Audio Visual Stimulation patterns intended to produce a therapeutic benefit.

Drug:
• Sana Device (Control)
A control device that mimics the physcial appearance of the Sana device.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Sana Health	University of Pennsylvania

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Fibromyalgia Symptoms	To confirm the superiority of the active arm over sham on changes in quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR)	6 weeks
Secondary	Changes in Generalized Anxiety Symptoms	To confirm the superiority of the active arm over sham on generalized anxiety as measured by Generalized Anxiety Disorder 7-item (GAD-7)	6 weeks
Secondary	Changes in Depression Symptoms	To confirm the superiority of the active arm over sham on depression sypmtoms as measured by the Patient Health Questionnaire-8 (PHQ-8)	6 weeks
Secondary	Changes in Sleep Quality	To confirm superiority of the active arm over sham on sleep quality as measured by the PROMIS 4a Sleep Disturbance Scale (PR4A)	6 weeks
Secondary	Changes in Pain	To confirm the superiority of the active arm over sham on reduction of pain as measured by the Pain Enjoyment General-Activity (PEG) scale	6 weeks
Secondary	Perceived Change in Quality of Life	To examine the effect of the active arm on perceived change in quality of life as measured by the Patient Global Impression of Change (PGIC) scale	6 weeks